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Introduction
Fabry's disease (a-galactosidase-deficiency), an inborn
error of glycosphingolipid metabolism, results from
the defective activity of the lysosomal enzyme a-galac-
tosidase. The enzymatic defect, transmitted by an
X-linked recessive gene, leads to the progressive accu-
mulation of neutral glycosphingolipids with terminal
a-galactosyl moieties in most visceral tissues and body
fluids. Characteristic clinical manifestations of the dis-
ease are onset of pain and paraesthesias in the extrem-
ities, vessel ectasia (angiokeratomata) in skin and
mucous membranes, and hypohidrosis during child-
hood or adolescence. Corneal and lenticular opacities
are early findings. With increasing age renal failure
and a dilated cardiomyopathy can develop. Kidney
transplantation successfully corrects renal insufficiency
[1] and was regarded by some authors as a possible
way for correcting not only renal insufficiency, but
also the enzymatic deficiency by replacement of a-
galactosidase through the transplanted kidney [2,3].
We report a case of Fabry's disease in which the disease
recurred in the transplanted kidney 14 years after
successful renal transplantation.
Case report
Our male patient was born in 1947, and did well until
1974 when for the first time impaired renal function
was described. In 1978 the diagnosis of Fabry's disease
was made. There were typical opacities in the corneas
as well as skin changes (angiokeratomatas). Ceramid-
trihexosid concentration was elevated in the urine. In
cultured fibroblasts of the skin a diminished activity
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of a-galactosidase was found. In the same year the
kidney function deteriorated and haemodialysis was
required.
One year later, the patient was successfully trans-
planted. A few days after transplantation a rejection
was postulated and the patient received 3 x 1000 mg
solumedrol i.v. The following course was unevent-
ful and renal function was stable until 1993.
Immunosuppressive maintenance therapy included
10 mg prednisone and 100 mg azathioprine. After
transplantation the patient became HBs-Ag and HBe-
Ag positive; it was suspected that he became infected
through six blood transfusions during the transplanta-
tion period. During follow-up chronic aggressive hep-
atitis B was diagnosed and the patient developed
cirrhosis of the liver. In 1981 he exhibited femur head
necrosis on both sides, probably related to steroid
medication after transplantation. Hip replacement was
performed in 1981 on the left side, and on the right
side in 1982. The patient was hospitalized in August
1985 because of deep-vein thrombosis of the left leg.
In 1987 a cholecystectomy was performed because of
acute cholecystitis; in the same year osteonecrosis of
the lateral femur condylus was diagnosed, eventually
due to Fabry's disease or steroid therapy.
During 1992 infection of the right hip joint with
Salmonella enteritidis was observed. Treatment with
ciprofloxacin was begun and a new artificial joint was
implanted.
In 1993 deterioration of the clinical status of the
patient began. Liver function became worse, the patient
gained weight and the kidney function deteriorated.
The patient was hospitalized. The diagnosis of activa-
tion of hepatitis B and liver cirrhosis was made and a
hepatorenal syndrome was suspected. Renal function
became worse despite treatment with vasoactive sub-
stances and volume substitution. In the end stage of
the disease, a continuous venovenous haemofiltration
was begun. The patient died 2 days later from car-
diac failure.
Autopsy findings
Autopsy was performed 27.5 h after death.
Morphological findings were: Excentric hypertrophy
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of both cardiac ventricles with signs of relative coron-
ary insufficiency, micronodular cirrhosis and cholest-
asis of the liver, adenoma of Papilla vateri, focuses of
infarction of the spleen, and atrophy of the adrenal
cortex. Deposits of ceramid-trihexosid were demon-
strable in walls of blood vessels, myocardial cells,
Kupffer cells and also in liver cells. The patient's own
kidney showed massive cortical atrophy and complete
loss of glomeruli. Residual tubules were dilated and
tubular epithelium appeared vacuolated in paraffin
sections (Figure 1). Electron-microscopy revealed mas-
sive deposits of ceramid-trihexosid in tubular epithe-
lium, tubular lumen, interstitial macrophages, and
endothelial cells. Although the kidney transplant was
of normal light-microscopic appearance, ultrastruc-
turally deposits of ceramid-trihexosid in endothelial
cells (Figure 2) as well as in tubular epithelium
(Figure 3) were observed.
Discussion
In this 46-year-old male patient, recurrent Fabry's
disease was noted in the transplanted kidney 14 years
after successful allotransplantation. There was an accu-
mulation of ceramid-trihexosid in several organs as
well as in tubular epithelial cells and endothelial cells
of the transplanted kidney.
The description of recurrence of Fabry's disease in
the transplanted kidney is rare. We found only four
other cases in the literature [4-7]. In 1981 we reported
a case from our centre in which, 14 years after success-
ful transplantation, no signs of de novo Fabry's disease
in the transplanted kidney could be found [8].
Four possibilities for recurrence can be thought of:
1. Inadequate enzyme replacement for complete meta-
bolization of the ceramid-trihexosid produced.
2. Increased production of ceramid-trihexosid, which
cannot be totally metabolized in presence of normal
enzyme activity. This seems to us the most probable
hypothesis. It explains why only small amounts of
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Fig. I. Patient's kidney (H&Ex460). Vacuolization of tubular
epithelium.
Fig. 2. Kidney transplant (EM x 3700, inset x 83 700). Formalin
fixed and refixed in glutaraldehyde. Endothelial cell showing extens-
ive ceramid-trihexosid deposition. Inset demonstrates lamellar struc-
tures with periodicity.
ceramid-trihexosid are found (that are seen only by
electron-microscopy) and why the deposits are
always in the vascular endothelium. Friedlander
et al. [4] performed a renal biopsy in a patient 8
years after transplantation with normal renal func-
tion. Light-microscopy showed no abnormalities,
but electron-microscopy revealed occasional small
myelin figures in the vascular endothelium compat-
ible with early accumulation of ceramid-trihexosid.
Mosnier et al. [5] also described a case in which
autopsy was performed II years after successful
transplantation. Sphingolipid inclusions were found
in endothelial cells of capillaries by electron-
microscopy.
Recolonization of the graft vascular system through
host endothelium. This theory was formulated by
McMahon et al. [6]. They described a male patient
with blood group B, who was transplanted with a
kidney from a donor with blood group O. They
showed, that the donor allograft endothelium was
slowly replaced by cells displaying both cytoplasmic
metabolic inclusions and surface immunological
markers specific to the host phenotype with com-
plete recolonization of the graft vascular system by
host endothelium.
Presence of a circulating inhibitor of a-galactosid-
ase. Faraggiana et al. [7] described a patient who
died of heart failure 6 months after kidney trans-
Recurrence of Fabry's disease in a renal allograft
Fig. 3. Kidney transplant (EM x 900, inset x 83 700). Formalin fixed
and refixed in glutaraldehyde. Tubular epithelium snowing ceramid-
trihexosid deposition. Inset demonstrates lamellar structure with
periodicity.
plantation. They found a small number of typical
deposits in the transplanted kidney. In this case a
circulating a-galactosidase inhibitor was demon-
strated, but this was not investigated in our patient.
Survival of the allograft in our patient for 14 years
with well-maintained structure of the kidney at autopsy
suggests that the indication for kidney allotransplant-
ation is not limited by the possibility of graft failure
from recurrence of Fabry's disease.
For other organ damage it is expected that progres-
sion of pre-existing lesions should be slowed down.
Cardiac pathology in the patient reported included
mainly dilatation, which is compatible with normal
blood pressure without medical treatment observed
clinically. The possibility that the amount of ceramid-
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trihexosid deposited in myocardial cells contributed to
terminal cardiac insufficiency cannot be totally
excluded.
Concerning the course of hepatitis B, high antigen
titres up to 280 000 E/ml in the absence of anti-Hbs
antigen and positive Hbe antigenaemia in 1991 were
observed. GOT and GPT levels were elevated slightly
and intermittently during the whole course. This con-
stellation is very likely to be related to immunosuppres-
sive therapy. An influence of Fabry's disease of the
liver on the course of the hepatitis B infection seems
rather remote.
In summary, this case illustrates that kidney trans-
plantation cannot heal Fabry's disease by enzyme
transplantation in all patients. Several explanations for
recurrent disease are discussed which may explain the
variable occurrence of Fabry's deposits in transplanted
kidneys. Nevertheless a patient can be successfully
treated for kidney failure during an extended time
period. The extent of heart damage might decide the
long-term survival of patients (8, this report). Ethical
concern to include patients with Fabry disease in
transplantation programmes seems not to be justified
even in times of transplant organ shortage.
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